Vera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vera Therapeutics (VERA).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

12Buy

2Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$66Upside to Avg. PT+113.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Leerink Partners	Will Soghikian	Initiate	Market Perform	$34
Sep 8, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$76→$83
Aug 17, 2026	Wedbush	Laura Chico	Maintained	Neutral	$34
Aug 12, 2026	HC Wainwright & Co.	Arthur He	PT Cut	Buy	$125→$90
Aug 11, 2026	Wedbush	Laura Chico	PT Cut	Neutral	$43→$34
Jul 8, 2026	TD Cowen	Ritu Baral	PT Raise	Buy	$73→$78
Jul 8, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$56→$76
Jul 8, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$35
Jul 8, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$110→$125
Jul 7, 2026	B of A Securities	Dina Ramadane	PT Raise	Buy	$65→$70
May 15, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$95→$91
Mar 11, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$88
Mar 2, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$90→$110
Dec 19, 2025	B of A Securities	Dina Ramadane	PT Raise	Buy	$48→$66
Dec 19, 2025	Goldman Sachs	Paul Choi	PT Raise	Buy	$55→$95
Dec 19, 2025	JP Morgan	Anupam Rama	PT Cut	Overweight	$99→$96
Dec 11, 2025	Wedbush	Laura Chico	PT Raise	Neutral	$23→$33
Dec 8, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$75→$97
Dec 5, 2025	TD Cowen	Ritu Baral	PT Raise	Buy	$60→$73
Dec 3, 2025	JP Morgan	Anupam Rama	PT Raise	Overweight	$52→$99

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

Leerink Partners analyst Will Soghikian initiates coverage on Vera Therapeutics (NASDAQ:VERA) with a Market Perform rating and announces Price Target of $34.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $76 to $83.

Benzinga Newsdesk

PRO
Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

Wedbush analyst Laura Chico reiterates Vera Therapeutics (NASDAQ:VERA) with a Neutral and maintains $34 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $125 to $90.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $43 to $34.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

TD Cowen analyst Ritu Baral maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $73 to $78.

Benzinga Newsdesk

Vera Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Vera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

PRO
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

PRO
Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

PRO
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

People Also Watch

People Also Watch

Vera Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Vera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

PROJP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

PROWedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

PROHC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

PROWedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

PROTD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

People Also Watch

People Also Watch

PRO
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

PRO
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

PRO
Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

PRO
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78